Home
Browse
Search
Statistics
About
Usage
PMID: 1281220
Sheppard DN, Welsh MJ
Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents.
J Gen Physiol. 1992 Oct;100(4):573-91.,
[PubMed]
Sentences
No.
Mutations
Sentence
Comment
46
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:46:291
status:
NEW
view ABCC7 p.Lys1250Met details
MATERIALS AND METHODS For this study we used NIH 3T3 fibroblasts that had been stably infected with a retrovirus expressing either wild-type human CFTR (Gregory, Cheng, Rich, Marshall, Paul, Hehir, Ostedgaard, Klinger, Welsh, and Smith, 1990) or a CFTR mutant in NBD2 (CFIR-KI250M, in which
lysine 1250 was changed to methionine
) (Anderson et al., 1991a).
Login to comment
48
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:48:52
status:
NEW
view ABCC7 p.Lys335Glu details
We also transiently expressed another mutant (CFI'R-
K335E
, in which lysine 335 in the first transmembrane domain was changed to glutamic acid) in HeLa cells using the vaccinia virus-T7 hybrid expression system (Rich et al., 1990; Elroy-Stein, Fuerst, and Moss, 1989).
Login to comment
161
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:161:339
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:161:431
status:
NEW
view ABCC7 p.Lys1250Met details
We therefore examined the effect of glibenclamide, the most potent inhibitor we had identified, on CI- currents generated by several CFFR mutants. We studied 100 • 1992 CFTR containing mutations that affect each of the three types of domains of CFTR: CFFP~R where part of the R domain has been deleted (amino acids 708-835); CVFR-
K335E
, which contains a mutation in the sixth putative membrane-spanning sequence; and CFTR-
K1250M
, which contains a mutation in the second NBD.
Login to comment
171
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:171:5
status:
NEW
view ABCC7 p.Lys335Glu details
CFFR-
K335E
forms CI- channels that are similar to wild-type channels, except that the anion selectivity is altered such that I- > Br- > C1- and currents show some outward rectification (Anderson et al., 1991b and Fig. 7, D and F).
Login to comment
172
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:172:29
status:
NEW
view ABCC7 p.Lys335Glu details
Glibenclamide inhibited CFTR-
K335E
CI- currents, and the effect was similar to that observed with wild-type CFTR (Fig. 7, E and F).
Login to comment
173
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:173:98
status:
NEW
view ABCC7 p.Lys1250Met details
Comparison with ATP-dependent transporters suggest that mutations in the second NBD, such as CFTR-
K1250M
, are likely to abolish or impair the function of SHEPP~LRDANDWELSHK-ATP Channel Regulators Inhibit CFTR NBD2 (Anderson et al., 1991a).
Login to comment
174
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:174:19
status:
NEW
view ABCC7 p.Lys1250Met details
Nevertheless, CFFR-
K1250M
produces CI- channels that have cAMP-dependent regulation and biophysical properties that are similar to wild-type CFFR (see Anderson et al., 1991a, and Fig. 7, G and I).
Login to comment
175
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:175:19
status:
NEW
view ABCC7 p.Lys1250Met details
Inhibition of CFTR-
K1250M
CI- currents by glibenclamide was similar to that observed with wild-type CYI'R (Fig. 7, H and I).
Login to comment
176
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:176:58
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:176:95
status:
NEW
view ABCC7 p.Lys1250Met details
+SO mV 0 m V ~ -go mV CFTFI~ A~ ......~-1 baseline D CFTR-
K335E
I ii..i.Iii cAMP .... 13, CFTR-
K1250M
1cAMP baseline + gllbenclamlde 250 pA L 50 ms C 1500 1000 5OO -500 o1~0 -100 -75 -50 -25 0 V (mV) ---o-- baseline ---4-- gllbenclamlde E) I cAMP + gllbenclamlde / tp----e F 1000 750 5OO -100 -75 -50 -25 0 V (mV) H ) 1000 PAL__ 50 ms I i cAMP + gllbenclamlde --o-- cAMP --e-- gllbanclamlde / _~_ _ 4OOO 3OOO ~q]O0 I000 0 I000 2OOO 30OO mOO -100 -75 -50 -25 0 V (mV) 25 50 25 50 25 50 FIGURE 7.
Login to comment
178
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:178:99
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:178:153
status:
NEW
view ABCC7 p.Lys1250Met details
Traces are from C127 cells stably expressing CFTP-~R (A-C), HeLa cells transiently expressing CFFR-
K335E
(D-F), and NIH 3T3 cells stably expressing CFIR-
K1250M
(G-I).
Login to comment
180
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:180:67
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:180:82
status:
NEW
view ABCC7 p.Lys1250Met details
CFFRAR currents were recorded in the absence of cAMP, but for CFFR-
K335E
and CFTR-
K1250M
currents cAMP agonists were present.
Login to comment
185
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:185:116
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:185:136
status:
NEW
view ABCC7 p.Lys1250Met details
Data for steady-state current values measured at +50 and -90 mV are shown for wild-type CF-FR (A), CFTRAR (B), CFFR-
K335E
(C), and CFTR-
K1250M
(D).
Login to comment
186
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:186:50
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:186:66
status:
NEW
view ABCC7 p.Lys1250Met details
The dose-response curves for wild-type CFFR, CFTR-
K335E
, and CFTR-
K1250M
were similar.
Login to comment
187
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:187:374
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:187:423
status:
NEW
view ABCC7 p.Lys1250Met details
Although the effect was not marked, in each case inhibition was slightly more potent at -90 mV than at +50 inV. A 100 8O O 60 c g 20 B 100 8O o 6o eo o m 20 THE JOURNAL OF GENERAL PHYSIOLOGY • VOLUME 100 • 1992 C CFTR 100 ' --o-- 50mV 80 e 6o C g,m 2O 0 20 40 60 80 1C10 0 gllbenclamlde (,aM) D CFTRAR 100 80 2 60 c i 2O 1 ~ ~ 866o o glil~nclamlde (gM) CFTR-
K335E
0 20 40 ~ 80 100 glibenclamlda (,ttM) CFTR-
K1250M
"il o 2i~ ,o 6i) 8o lOO glibenclamlde (i.tM) FIGURE 8.
Login to comment
191
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:191:41
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:191:57
status:
NEW
view ABCC7 p.Lys1250Met details
(A) Wild-type CFTR; (B) CFTR~R; (C) CFTR-
K335E
; (D) CFFR-
K1250M
.
Login to comment
196
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:196:252
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:196:324
status:
NEW
view ABCC7 p.Lys1250Met details
Half-maximal inhibition by glibenclamide was similar in all cases, occurring at ~ 20 TABLE I1 Effect of Glibenclamide on CFTR Mutants 4-50 mV -90 mV Mutant Experiments Ki n Ki n my/ u2v/ CFTR 21.8 ± 5.2 0.8 - 0.1 19.0 - 5.6* 0.7 ± 0.1 7 CFTR-
K335E
25.9 ± 4.1 0.9 ± 0.I 20.4 +--3.7* 0.9 ± 0.1 6 CFTR-
K1250M
16.8 _ 4.2 0.8 ± 0.1 31.2 ± 2.5 1.0 - 0.1 5 Ki and n values were calculated as described in Table I for currents measured at +50 and -90 mV for the number of experiments listed.
Login to comment
199
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:199:184
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:199:204
status:
NEW
view ABCC7 p.Lys1250Met details
Half-maximal inhibition by glibenclamide, measured at -90 mV, showed a small but statistically significant increase in potency compared with that at +50 mV for wild-type CFTR and CFTR-
K335E
, but not CFFR-
K1250M
.
Login to comment
248
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:248:19
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:248:34
status:
NEW
view ABCC7 p.Lys1250Met details
Inhibition of CFTR-
K335E
and CFTR-
K1250M
CI- currents by glibenclamide resembled that of wild-type CFFR.
Login to comment
249
ABCC7 p.Lys335Glu
X
ABCC7 p.Lys335Glu 1281220:249:28
status:
NEW
view ABCC7 p.Lys335Glu details
ABCC7 p.Lys1250Met
X
ABCC7 p.Lys1250Met 1281220:249:38
status:
NEW
view ABCC7 p.Lys1250Met details
This suggests that residues
K335E
and
K1250M
do not form a critical part of the glibenclamide interaction site.
Login to comment